Purpose: The prognostic value of obesity in patients with renal cell carcinoma (RCC) remains controversial. This study aimed to assess the sex-dependent prognostic role of body mass index (BMI) in patients with nonmetastatic RCC who underwent radical or partial nephrectomy. Patients and methods: We retrospectively analyzed 643 consecutive patients with nonmetastatic RCC who underwent curative nephrectomy in our center between 2004 and 2014. Associations among BMI, sex, overall survival (OS), cancer-specific survival (CSS), and metastasis-free survival (MFS) were analyzed. Results: Males were more likely to have a higher BMI than females (BMI as a categorical variable: P<0.001; BMI as a continuous variable: P=0.002). In men, a high BMI was significantly correlated with better 5-year OS, CSS, and MFS rates (P=0.001, 0.014, and 0.001, respectively), and multivariate analysis identified that a high BMI was independently associated with greater OS, CSS, and MFS (OS: hazard ratio [HR]=0.207, P=0.011; CSS: HR=0.225, P=0.005; MFS: HR=0.243, P=0.004). However, in women, there was no significant difference in 5-year OS, CSS, and MFS rates according to BMI (P=0.781, 0.812, and 0.538, respectively). Moreover, a high BMI was no longer independently associated with OS, CSS, or MFS (P=0.821, 0.832, and 0.801, respectively). Among patients with clear cell RCC, BMI was significantly associated with OS, CSS, and MFS only among men (all P<0.05) and not among women (all P>0.05). Conclusion: Among patients with nonmetastatic RCC, a high BMI was a favorable prognostic factor in males rather than females. Therefore, sex might influence the correlation between obesity and urological outcomes in nonmetastatic RCC.
Introduction
Renal cell carcinoma (RCC) is one of most common malignant tumors of the kidney; its global incidence has increased by about 2% in the last two decades.
Obesity, as characterized by body mass index (BMI), is a well-known risk factor for RCC, 6 and the relative risks of RCC increase consistently with obesity in a doseresponse manner. 7 However, the prognostic value of obesity in RCC patients remains a controversy, with some studies even demonstrating contradictory findings. Some researchers reported no significant relationship between obesity and urological outcomes in RCC, [8] [9] [10] while some others argued that obesity is an independent predictor of prognosis. 11, 12 Furthermore, a previous study demonstrated a nonlinear association between obesity and RCC prognosis. 13 This phenomenon was called the "obesity paradox". 14 Therefore, we hypothesized that the significance of obesity in RCC prognosis might be influenced by some factor(s). A recent study found that a higher BMI is significantly associated with increased risk of RCC among men, but not among women, 15 suggesting that the relationship between obesity and urological outcomes in RCC might be sexspecific. However, to date, only few studies have reported the prognostic role of obesity in RCC patients according to sex, and the results were conflicting. 10, 16, 17 Therefore, this present study aimed to evaluate the sex-dependent role of BMI in predicting the survival outcomes of patients with nonmetastatic RCC who underwent radical or partial nephrectomy.
Patients and methods Patients
After obtaining institutional review board approval, we retrospectively reviewed 803 consecutive patients with nonmetastatic RCC (pathological T1-4N0M0) following radical or partial nephrectomy between January 2004 and July 2014 at the First Affiliated Hospital of Wenzhou Medical University.
The following were excluded from the study: patients with kidney transplantation before surgery, with only one kidney, or with hemodialysis therapy (n=29); patients with a history of any cancer, bilateral RCC, or prior surgery for RCC (n=51); and patients with BMI<18.5 kg/m 2 (n=29).
Patients with incomplete preoperative medical information were also excluded (n=51) ( Figure 1 ). In addition, neoadjuvant chemotherapy was not performed in any patients preoperatively. Finally, 643 patients were included for analysis.
Variables
The clinicopathological characteristics of patients according to sex are shown in Table 1 . These variables were ; obesity). [18] [19] [20] The T stage and histological subtype of tumors were determined based on the seventh edition of the TNM classification by the Union for International Cancer Control, the guidelines by the American Joint Committee on Cancer, and the Heidelberg recommendations. Nuclear grade was evaluated using the Fuhrman grading system. Tumor size was defined as the largest diameter of the tumor according to the pathological report. The pathological features of tumors were evaluated by urological pathologists. Postoperative follow-up care consisted of blood and urine tests, and chest and abdominal computed tomography or magnetic resonance imaging every 3 to 6 months for the first 2 years and annually thereafter. The follow-up cutoff was September 1, 2016. Overall survival (OS), cancer-specific survival (CSS), and metastasis-free survival (MFS) were calculated from the date of surgery to the (a) date of death from any cause, (b) date of causespecific death, and (c) date of the last follow-up of recurrence of radiologically or histologically confirmed distant metastasis, respectively.
Statistical analysis
All statistical analyses were performed using SPSS software package version 25.0 (IBM, Armonk, NY 
Results
Associations between BMI, sex, and clinical and pathological characteristics Figure 2A) ; however, BMI in women tended to increase with age (r=0.007, P=0.656) ( Figure 2B ). In addition, men were more likely to be anemia and had higher risk of metastasis (P=0.038 and P=0.029, respectively).
Overall survival according to BMI and sex
During the follow-up, 57 (8.9%) patients died (Table 1) . In all population, the 5-year OS rates were 88.7% and 97.8% in patients with normal BMI and high BMI, respectively (P=0.004) ( Figure 3A ). BMI was identified as an independent favorable factor of OS (BMI as a categorical variable: HR=0.326, P=0.021; BMI as a continuous variable: HR=0.857, P=0.027) through univariate analysis and multivariate analysis (Tables S1-S3, Table 2 , and Figure 4A and B). In men, the 5-year OS rates were 85.5% and 98.1% in patients with normal BMI and high BMI, respectively (P=0.001) ( Figure 3B ). BMI was also identified as an independent favorable factor of OS in men (BMI as a categorical variable: HR=0.207, P=0.011; BMI as a continuous variable: HR=0.805, P=0.012) according to univariate analysis and multivariate analysis (Table 3 , and Figure 4 ). However, in women, there was no significant difference between normal BMI patients and high BMI patients with 93.3% and 91.8% 5-year OS rates, respectively (P=0.781) ( Figure 3C ). Furthermore, BMI was not an independent predictor of OS in women (BMI as a categorical variable: HR=1.201, P=0.821; BMI as a continuous variable: HR=0.990, P=0.934) ( Table 3 , and Figure 4 ).
CSS according to BMI and sex
During the follow-up, 39 (6.1%) patients died due to RCC (Table 1) . In all population, the 5-year CSS rates were 91.6% and 97.3% in patients with normal BMI and high BMI, respectively (P=0.029) ( Figure 5A ). BMI was identified as an independent favorable factor of CSS (BMI as a categorical variable: HR=0.425, P=0.019; BMI as a continuous variable: HR=0.891, P=0.047) using univariate analysis and multivariate analysis (Table S2, Tables 4 and 5 , and Figure 6 ). In men, the 5-year CSS rates were 90.4% and 99.1% in patients with normal BMI and high BMI, respectively (P=0.014) ( Figure 5B ). BMI was also identified as an independent favorable factor of CSS in men (BMI as a categorical variable: HR=0.225, P=0.005; BMI as a continuous variable: Correlation between age and BMI. The BMI in men significantly decreased when they were ageing (A); however, the BMI in women increased with increasing age while the relationship was not significant (B). Abbreviation: BMI, Body mass index.
HR=0.817, P=0.027) according to univariate analysis and multivariate analysis (Table 5 , and Figure 6 ). Nevertheless, in women, the 5-year CSS rates were 93.3% and 91.8% in patients with normal BMI and high BMI, respectively. There was no significant difference between the two groups (P=0.812) ( Figure 5C ), and BMI was not an independent 
P=0.784
Following-up duration (months) 96 144 Figure 6A and B).
MFS according to BMI and sex
During the follow-up, 71 (11.0%) patients experienced metastasis (Table 1) . In all population, the 5-year MFS rates were 85.7% and 96.6% in patients with normal BMI and high BMI, respectively (P=0.002) ( Figure 7A ). BMI was identified as an independent favorable factor of MFS (BMI as a categorical variable: HR=0.331, P=0.007; BMI as a continuous variable: HR=0.895, P=0.047) using univariate analysis and multivariate analysis (Table S3, Tables 6 and 7 , and Figure  8 ). In men, the 5-year MFS rates were 90.4% and 99.1% in patients with normal BMI and high BMI, respectively (P=0.001) ( Figure 7B ). BMI was also identified as an independent favorable factor of MFS in men (BMI as a categorical variable: HR=0.243, P=0.004; BMI as a continuous variable: HR=0.865, P=0.044) according to univariate analysis and multivariate analysis (Table 7 , and Figure 8 ). Nevertheless, in women, the 5-year MFS rates were 93.3% and 91.8% in patients with normal BMI and high BMI, respectively. There was no significant difference between the two groups (P=0.538) ( Figure 7C ), and BMI was not an independent 
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Following-up duration (months) 96 144 Figure 5 Kaplan-Meier curves for cancer-specific survival stratified by BMI in all patients (A), male patients (B), and female patients (C) with non-metastasis RCC. Abbreviations: BMI, body mass index; RCC, renal cell carcinoma. Figure 8A and B).
Associations between BMI, sex, and urological outcomes in patients with clear cell RCC
As shown in Table 8 , there were 367 (65.3%) males and 195 (34.7%) females, with a male-to-female ratio of 1.88:1. Men were more likely to have significantly higher BMI than women (P<0.05). There were no significant differences between men and women in terms of other factors. As shown in 
Discussion
The results of this study revealed that BMI was an independent predictor of OS, CSS, and MFS in patients with nonmetastatic RCC following nephrectomy. Such findings were consistent with those of previous studies.
11 ,12,21 However, in the subgroup analysis, men had 
P=0.538
Follow-up duration (months) 96 144 Figure 7 Kaplan-Meier curves for metastasis-free survival stratified by BMI in all patients (A), male patients (B), and female patients (C) with non-metastasis RCC. Abbreviations: BMI, body mass index; RCC, renal cell carcinoma.
a significantly higher BMI than women. Moreover, a high BMI was significantly associated with favorable OS, CSS, and MFS in men, but not in women, with RCC. The same findings were observed among patients with clear cell RCC. To our knowledge, this is the first study to assess the prognostic influence of BMI on nonmetastatic RCC according to sex.
To date, four studies have assessed the associations between sex, BMI, and survival outcomes in RCC. 10, 16, 17, 22 Donat et al (2006) retrospectively reviewed 1137 consecutive patients with RCC who underwent radical or partial nephrectomy between 1995 and 2003, to evaluate the influence of BMI on survival in RCC patients. 10 Their results did not show a significant difference in OS or progression-free 17 Their results demonstrated that BMI is significantly associated with CSS among all patients and men, but not among women.
Although their results were consistent with ours, their research had two limitations: First, the male-to-female ratio of 2.7:1 for RCC was much higher than the recommended ratio of 1.5:1 reported in the guidelines. 3 The sample size of females was only 117, which was relatively small for subgroup analysis. Second, their study also included patients with metastasis, with 44 (10.1%) patients of the whole population having metastasis before surgery. Meanwhile, Byun et al analyzed 2097 patients with nonmetastatic clearcell RCC who underwent surgery. 16 They also reported that a high BMI is associated with greater recurrence-free survival or CSS rates among all patients and men, but not among women. Although their study had a large sample size, there were 1524 males and only 573 females, resulting in a male-to -female ratio as high as 2.6:1. This finding might attenuate any putative associations between sex, BMI, and RCC prognosis. Our study has several advantages over the four studies mentioned above. 10, 16, 17, 22 First, we only included patients with nonmetastatic RCC (pathological T1-4N0M0) and excluded those with metastasis before surgery, because the presence of metastasis might influence the analysis of associations between sex, BMI, and survival outcomes in RCC. Second, our study included 414 males and 229 females, resulting in a male-to female ratio of 1.81:1, which is close to 1.5:1. Lastly, we included the majority of well-known accepted prognostic factors of nonmetastatic RCC, including age, nuclear grade, histological subtype, tumor necrosis, tumor size, and pathological stage. The obesity paradox has been observed in several studies, 23 but its cause remains unclear. Our findings suggest that sex should be considered when evaluating the prognostic value of obesity in RCC prognosis. However, it is unclear why the relationship between obesity and RCC prognosis may be sex-specific. One hypothesis is that changes in hormones and genetic expression, which are two sex-specific factors, may influence the magnitude of the prognostic role of obesity in RCC. A previous study revealed that the body weight of women would reach its maximum during menopause and their relative body fat and abdominal fatness would increase with advancing age. 24 In our study, there was a trend toward an increased BMI with increasing age in females, although the relationship was not significant (P=0.656). These physiological features are regulated by hormonal changes and may lead to significant differences in predicting the RCC prognosis according to BMI between men and women. Regarding to the genomic characteristics of RCC between men and women, Lucca et al reported that immune-or inflammation-associated genes are more likely to overexpress in males, while catabolic process-related genes tend to overexpress in females. 25 Brannon et al performed a metaanalysis of studies on gene expression in clear cell RCC. In their study of 366 autosomal genes, they identified 326 (89.1%) genes as differentially expressed between the sexes. Furthermore, some of these gene participate in important biological processes, including DNA repair (PARP8 and ERCC5), cell signaling (MAPKSP1, SPAG1, etc.) and cell motility (VCAN and CYR61). 26 A previous study also analyzed three large-scale clear cell RCC mutation sequencing projects. Their results revealed that mutation of the BAP1 gene was significantly associated with poorer OS in the whole population and among females, but not among males. Furthermore, they concluded that the combination of sex and mutation of a specific gene, such as BAP1, may be associated with OS in RCC patients.
27
Our study has several limitations. First, it has a retrospective design and was conducted in a single institution, which might have led to selection bias. Nevertheless, our department is the largest urological center with the largest sample size for RCC patients in the south of Zhejiang Province; therefore, our data were representative and reliable. Second, we were unable to include some potential predictors, such as smoking history and nutritional status, due to lack of patient information. The antecedent weight loss, which might have influenced the outcomes, was also not reported. However, we had included the majority of well-known accepted prognostic factors of nonmetastatic RCC. Lastly, we were also unable to obtain information on waist circumference, waist-to-hip ratio, and visceral adiposity that could further improve the understanding of the prognostic role of obesity in survival outcomes in RCC patients. Nevertheless, BMI is the most widely used index for obesity in clinical practice. Thus, further prospective studies and basic researches are required to investigate the sex-dependent prognostic value and mechanisms of BMI in RCC patients.
Conclusion
Our study showed that a high BMI was a favorable prognostic factor in patients with nonmetastatic RCC who underwent nephrectomy. However, when the patients were stratified according to sex, BMI was significantly associated with OS, CSS, and MFS only among men, and not among women. The same findings were observed among patients with clear cell RCC. Our results suggest that sex may influence the relationship between obesity and prognosis of nonmetastatic RCC.
Abbreviation list
RCC, renal cell carcinoma; BMI, body mass index; OS, overall survival; MFS, metastasis-free survival; CSS, cancer-specific survival; CKD, chronic kidney disease; DM, diabetes mellitus. 
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